Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiprelestat - Proteo Biotech

Drug Profile

Tiprelestat - Proteo Biotech

Alternative Names: Elafin

Latest Information Update: 28 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Proteo Biotech
  • Developer Proteo Biotech; Rhein Minapharm Biogenetics; Stanford University
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Recombinant proteins
  • Mechanism of Action Leucocyte elastase inhibitors; Myeloblastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pulmonary hypertension; Oesophageal cancer; Postoperative inflammation
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial reperfusion injury; Postoperative inflammation
  • Phase I Pulmonary arterial hypertension
  • No development reported Lung disorders; Lung transplant rejection

Most Recent Events

  • 28 Jan 2020 No recent reports of development identified for preclinical development in Lung-disorders(In neonates) in USA (Parenteral)
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Lung-transplant-rejection(Prevention) in USA (Parenteral)
  • 18 Mar 2019 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in USA (SC, Injection)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top